Pfizer (NYSE:PFE) Stock Price Down 1.3% – Here’s What Happened

Shares of Pfizer Inc. (NYSE:PFE) dropped 1.3% on Friday. The company traded as low as $29.81 and last traded at $30.0350. 29,374,521 shares were traded during trading, a decline of 26% from the average daily volume of 39,817,227 shares. The stock had previously closed at $30.42.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer completed a Phase 1 study of PF-07999415, providing an early development milestone and potentially adding value to its pipeline. The update does not yet establish efficacy or commercial potential, but it offers investors another clinical program to monitor. Pfizer PF-07999415 Phase 1 update
• Positive Sentiment: Pfizer signed a research and licensing agreement with Enodia Therapeutics focused on Sec61 inhibitors. The deal gives Pfizer rights to discover, develop and potentially commercialize candidates from Enodia’s platform, supporting efforts to replenish its drug pipeline through external innovation. Pfizer Enodia Sec61 collaboration
• Neutral Sentiment: A Swedish real-world study of Pfizer’s Ibrance is supplying additional evidence about the product’s use in clinical practice. The update may help support the franchise, but the available report does not indicate a material change to revenue expectations. Pfizer Swedish Ibrance study
• Neutral Sentiment: Pfizer’s roughly 5.7% dividend yield remains attractive to income investors, but comparisons with Bristol Myers Squibb and Merck emphasize that the high payout may reflect concerns about earnings consistency and dividend coverage. Pfizer dividend comparison
• Negative Sentiment: Pfizer is being pulled into a broader selloff involving Moderna and Merck after investors reacted negatively to melanoma-vaccine results that were positive but apparently below elevated expectations. The episode is weighing on sentiment across pharmaceutical and biotechnology stocks, even though Pfizer is not the developer of Moderna’s vaccine. Biotech selloff affecting Pfizer
• Negative Sentiment: Higher interest rates can make Pfizer’s high-yield dividend less competitive relative to bonds and increase pressure on valuation, particularly while the company works through uneven revenue trends and post-pandemic portfolio changes. Interest rates and Pfizer dividend stocks

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. HSBC raised their price target on Pfizer from $28.00 to $30.00 and gave the company a “hold” rating in a report on Thursday, September 10th. Bank of America dropped their price objective on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, July 10th. BMO Capital Markets cut their target price on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research report on Monday, July 13th. JPMorgan Chase & Co. raised their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 9th. Finally, Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. Five equities research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and a consensus target price of $28.72.

Pfizer Stock Down 1.3%

The firm’s 50-day simple moving average is $28.33 and its 200 day simple moving average is $26.63. The company has a market cap of $171.19 billion, a P/E ratio of 39.52, a PEG ratio of 2.04 and a beta of 0.32. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The company had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the prior year, the business posted $0.78 EPS. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 5.7%. The ex-dividend date is Friday, November 6th. Pfizer’s dividend payout ratio is currently 226.32%.

Hedge Funds Weigh In On Pfizer

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PFE. Bank Pictet & Cie Europe AG grew its position in shares of Pfizer by 5.6% during the 3rd quarter. Bank Pictet & Cie Europe AG now owns 338,410 shares of the biopharmaceutical company’s stock worth $9,651,000 after buying an additional 18,032 shares during the period. Cornerstone National Bank & Trust Co raised its position in shares of Pfizer by 37.7% in the 3rd quarter. Cornerstone National Bank & Trust Co now owns 2,065 shares of the biopharmaceutical company’s stock valued at $58,000 after acquiring an additional 565 shares during the period. MBM Wealth Consultants LLC raised its position in shares of Pfizer by 22.9% in the 3rd quarter. MBM Wealth Consultants LLC now owns 22,666 shares of the biopharmaceutical company’s stock valued at $646,000 after acquiring an additional 4,229 shares during the period. Onyx Bridge Wealth Group LLC boosted its stake in Pfizer by 2.1% during the 3rd quarter. Onyx Bridge Wealth Group LLC now owns 49,253 shares of the biopharmaceutical company’s stock worth $1,405,000 after acquiring an additional 1,006 shares during the last quarter. Finally, Banque Pictet & Cie SA bought a new position in Pfizer during the 3rd quarter worth approximately $252,000. Institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.